Tremfya (guselkunmab) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): ____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION		DISDENSING	INFORMATION
MEDICATION	OR WILDICAL	DISFLINSING	

MEDICATION NAME: DOSE/STRENGTH: FREQUENCY: LENGTH OF QUANTITY: **THERAPY/REFILLS:** NEW THERAPY **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES): Continued on next page

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management - Commercial Clients. Revision Date: 7.1.25 CAT009



Tremfya (guselkunmab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
	OTHER MEDICATIONS FOR THIS	CONDITION?		
YES (if yes, complete below) MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Plaque psoriasis Psoriatic arthritis Ulcerative colitis Crohn's disease 	ICD-10 Code(s):			
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORI	ATION: PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION		
Is patient going to be using drug	in combination with a clinical trial	? 🗌 Yes 🔲 No		
Initial Request: Will the patient be using Tremfya concurrently with another biologic response modifier or immunomodulatory agent? □ Yes □ No Will patient stop use of their biologic response modifier or immunomodulatory agent when they start use with Tremfya? □ Yes □ No				
Has the patient had a 3-month trial and inadequate response to the Humira biosimilar adalimumab- aacf? □ Yes □ No Please submit documentation.				
Does patient have an absolute contraindication to the biosimilar adalimumab-aacf? \Box Yes \Box No Please submit documentation.				
Has the patient tried and had an inadequate response to a 4- month trial of the <u>biosimilar</u> for Stelara- <u>Otulfi(ustekinumb-aauz</u>)? □ Yes □ No Please submit documentation.				
Does patient have a absolute contraindication to the biosimilar for Stelara- <u>Otulfi(ustekinumb-aauz</u>)?				
Is Tremfya prescribed by a derma Is Tremfya prescribed by a rheum Is Tremfya prescribed by a gastro	natologist? 🗆 Yes 🗆 No			
10% of BSA with involvement of	<u>Arthritis</u> : overing at least 10% of their body s palms, soles, head and neck, or ge □ Yes □ No			
•	lanagement LLC, a Prime Therapeuti Commercial Clients. Revision Date: 7			

FIIIG **THERAPEUTICS**[™]

CAT009

Tremfya (guselkunmab) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: ______ MEMBER'S FIRST NAME: _____

Has the patient had an inadequate response to topical therapy (e.g., corticosteroids, anthralin, calcipotriene, tazarotene)?* Yes No		
Select if the patient has had a trial and inadequate response to the following phototherapy options: Psoralens with UVA light (PUVA) UVB with coal tar 		
Has patient had a trial and failure with a three-month course of one of the following conventional disease modifying anti-rheumatic agents (DMARDs) [e.g., methotrexate, acitretin, sulfasalazine [Azulfidine®], leflunamide [Arava®] or hydroxychloroquine or cyclosporine)?		
Does the patient have documentation of a contraindication to all conventional DMARD systemic therapies indicated for their disease? □ Yes □ No *Must provide documentation		
For Ulcerative colitis: Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine and/or 6-mercaptopurine? Yes No Please provide documentation.		
For Crohn's Disease: Has patient had a trial of glucocorticoid therapy or methotrexate or azathioprine or 6-mercaptopurine or 5-ASA/mesalamine? Yes No Please submit documentation.		
<u>Renewal Request:</u> Is prescriber a dermatologist? □ Yes □ No Is prescriber a rheumatologist? □ Yes □ No Is Tremfya prescribed by a gastroenterologist? □ Yes □ No		
Is patient continuing to respond to therapy? Yes No Please submit documentation. 		
Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent? Yes No 		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?		
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.		
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.		
Prescriber Signature or Electronic I.D. Verification: Date:		

© 2017–2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.25 CAT009



Tremfya (guselkunmab) **Prior Authorization Request Form** Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: ____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

